San Mateo, California, USA, November 11, 2026
Helix has launched its Research Access Program, offering selected academic and nonprofit researchers access to linked clinicogenomic data from the Helix Research Network®. The initiative is designed to support population-scale research into the genetic basis of disease, clinical outcomes and more personalized approaches to healthcare. Approved researchers will access the datasets through Helix Research Workspaces, a new Trusted Research Environment (TRE) that provides a secure setting for exploring and analyzing clinicogenomic information. The pilot program is intended for a limited group of approved projects at non-commercial research institutions. Its launch follows the presentation of new findings at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, demonstrating how large-scale genomic data can contribute to preventive healthcare and understanding differences in treatment response. The research highlighted by Helix includes population genomic screening for inherited conditions and the potential influence of rare genetic variants on responses to GLP-1-based medicines.
Helix Opens Secure Access to Clinicogenomic Data
Through the Research Access Program, eligible academic and nonprofit researchers can apply to use linked clinical and genomic datasets from the Helix Research Network. The program is intended to help investigators examine genetic variation across clinical populations, explore disease-associated variants and generate evidence that may support advances in precision medicine. Access is provided through Helix Research Workspaces, using its Explorer environment within a Trusted Research Environment. The company plans to approve a select number of projects as part of the pilot, rather than offering unrestricted access to the dataset. Researchers from non-commercial institutions can apply for consideration and, if approved, use the available data for research projects that meet the program’s requirements. The initiative aims to address an important challenge in genomic research: connecting genetic information with real-world clinical data to understand how inherited factors influence health outcomes. By making these linked datasets available to qualified investigators, Helix aims to support research into disease risk, population-level genetic patterns and potential opportunities for earlier clinical intervention. The company says the program will help expand collaboration between its research network and the wider academic community.
Large-Scale Genomic Screening Shows Preventive Care Potential
One of the studies presented at ASHG 2026 examined outcomes among 527,000 participants screened for three Centers for Disease Control and Prevention (CDC) Tier 1 genomic conditions: Hereditary Breast and Ovarian Cancer (HBOC), Lynch syndrome and Familial Hypercholesterolemia (FH). These inherited conditions are associated with increased lifetime risks of cancer or cardiovascular disease, but individuals carrying relevant genetic variants may not have a known family history or noticeable symptoms when identified. According to the three-year outcomes study, participants who received positive genetic results were more likely to begin condition-specific screening than non-carriers. For individuals with HBOC and Lynch syndrome, the median age at preventive cancer screening was five to ten years younger after genetic results were returned compared with the period before results were available. The study also reported that, within one year of receiving results, the proportion of eligible carriers who started or intensified preventive treatment or underwent risk-reducing surgery nearly doubled, increasing from approximately one in five to one in three. Among participants who began condition-specific screening, carriers were six to eight times more likely than non-carriers to have a relevant finding within one year. Reported findings included elevated LDL cholesterol in FH, breast cancer in HBOC and colorectal cancer in Lynch syndrome. These observations suggest that population genomic screening may help identify previously unrecognized health risks and encourage earlier preventive action. However, the findings represent associations observed in the study and should be interpreted in the context of its design and participating health systems.
Advertisement
Genetic Variants May Influence GLP-1 Treatment Response
A second study presented at ASHG 2026 explored whether rare genetic variants affecting the GLP-1 receptor (GLP1R) could help explain differences in weight-loss responses to two widely used medicines: semaglutide and tirzepatide. Semaglutide acts through the GLP-1 receptor, while tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. The analysis found that participants carrying rare GLP1R variants associated with impaired receptor function experienced less weight loss with semaglutide than matched non-carriers, with reported weight loss of 2.4% compared with 8.8%. In contrast, the response to tirzepatide was not significantly different between the two groups, with reported weight loss of 13.3% among variant carriers and 15.2% among matched non-carriers. The study also found no association between GIP receptor (GIPR) variants and differential response to either medicine. These findings offer genetic evidence that differences in receptor function may contribute to variation in treatment response and could inform future research into personalized obesity care. Helix’s Research Access Program may provide additional opportunities for investigators to examine such relationships across larger clinical populations. By connecting genomic information with real-world health data, the company aims to support discoveries that can ultimately contribute to more targeted prevention and treatment strategies.
Source: Helix press release
